LGALS3 as a prognostic factor for classical Hodgkin's lymphoma

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Galectin-3 (LGALS3) is a lectin involved in tumor progression by inhibiting apoptosis.
• LGALS3 shares structural similarities with BCL2, another protein implicated in cell survival.
• The prognostic value of LGALS3 and BCL2 in classical Hodgkin's lymphoma (cHL) requires further investigation.

Purpose of the Study:

• To evaluate the prognostic significance of LGALS3 and BCL2 expression in patients with classical Hodgkin's lymphoma.
• To determine if LGALS3 or BCL2 expression can predict survival outcomes in cHL.
• To identify potential therapeutic targets or patient subgroups requiring intensified treatment.

Main Methods:

• Retrospective analysis of diagnostic tissues from 110 uniformly treated cHL patients.
• Immunohistochemical assessment of LGALS3 and BCL2 protein expression in Hodgkin/Reed-Sternberg cells.
• Statistical analysis including survival analysis and multivariate analysis.

Main Results:

• LGALS3 protein expression was observed in 25% of patients and was significantly associated with poor overall survival (P=0.007) and event-free survival (P<0.001).
• BCL2 protein expression was found in 14% of patients but showed no association with survival outcomes (P=0.928 and P=0.900).
• LGALS3 was identified as an independent prognostic factor for event-free survival (P=0.007) and showed prognostic value in limited-stage cHL.

Conclusions:

• LGALS3 protein expression is an independent prognostic factor in classical Hodgkin's lymphoma.
• LGALS3 may help identify limited-stage cHL patients who could benefit from more intensive therapy.
• BCL2 expression did not demonstrate prognostic significance in this cohort.